NASDAQ:ENTX Entera Bio Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $1.62 +0.01 (+0.62%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$1.50▼$1.6950-Day Range$1.57▼$2.9552-Week Range$1.43▼$6.60Volume45,648 shsAverage Volume32,014 shsMarket Capitalization$38.39 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Stock Forecast (MarketRank)Overall MarketRank™1.58 out of 5 starsMedical Sector978th out of 1,411 stocksBiological Products, Except Diagnostic Industry149th out of 215 stocksAnalyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Entera Bio has a forecasted upside of 455.6% from its current price of $1.62.Amount of Analyst CoverageEntera Bio has received no research coverage in the past 90 days. Previous Next 4.4 Community Rank Outperform VotesEntera Bio has received 167 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEntera Bio has received 85 “underperform” votes. (Add your “underperform” vote.)Community SentimentEntera Bio has received 66.27% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Entera Bio and other stocks. Vote “Outperform” if you believe ENTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 23.87% of the stock of Entera Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entera Bio are expected to decrease in the coming year, from ($0.75) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Entera Bio (NASDAQ:ENTX)Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Read More ENTX Stock News HeadlinesJune 17, 2022 | finance.yahoo.comEntera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside OpportunitiesMay 18, 2022 | seekingalpha.comEntera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | seekingalpha.comEntera Bio names Miranda Toledano as CBO, CFOMay 12, 2022 | finance.yahoo.comEntera Bio Reports First Quarter 2022 Financial Results and Business HighlightsMay 5, 2022 | finance.yahoo.comEntera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule TherapeuticsApril 28, 2022 | finance.yahoo.comEntera Bio to Report First Quarter 2022 Financial Results on May 12March 22, 2022 | finance.yahoo.comEntera Bio to Present at 2022 Maxim Virtual Growth ConferenceMarch 16, 2022 | finance.yahoo.comCompanies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In GrowthMarch 8, 2022 | benzinga.comRecap: Entera Bio Q4 EarningsMarch 8, 2022 | finance.yahoo.comEntera Bio Reports Financial Results for the Year Ended December 31, 2021March 3, 2022 | finance.yahoo.comEntera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022February 17, 2022 | finance.yahoo.comEntera Bio to Present at Aegis Virtual Conference on February 23rdFebruary 15, 2022 | nasdaq.comEntera Bio Ltd. Ordinary Shares (ENTX)See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTX CUSIPN/A CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees18Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/26/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+455.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12.19 million Net Margins-1,345.02% Pretax Margin-2,847.93% Return on Equity-27.70% Return on Assets-24.38% Debt Debt-to-Equity RatioN/A Current Ratio9.27 Quick Ratio9.27 Sales & Book Value Annual Sales$570 thousand Price / Sales67.36 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book1.71Miscellaneous Outstanding Shares23,700,000Free FloatN/AMarket Cap$38.39 million OptionableNot Optionable Beta1.65 Entera Bio Frequently Asked Questions Should I buy or sell Entera Bio stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Entera Bio stock. View analyst ratings for Entera Bio or view top-rated stocks. What is Entera Bio's stock price forecast for 2022? 2 Wall Street research analysts have issued 12 month price targets for Entera Bio's shares. Their ENTX stock forecasts range from $6.00 to $12.00. On average, they anticipate Entera Bio's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price. View analysts' price targets for Entera Bio or view top-rated stocks among Wall Street analysts. How has Entera Bio's stock performed in 2022? Entera Bio's stock was trading at $2.8150 at the start of the year. Since then, ENTX shares have decreased by 42.5% and is now trading at $1.62. View the best growth stocks for 2022 here. When is Entera Bio's next earnings date? Entera Bio is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Entera Bio. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) posted its quarterly earnings results on Thursday, May, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. Entera Bio had a negative trailing twelve-month return on equity of 27.70% and a negative net margin of 1,345.02%. During the same period in the prior year, the business posted ($0.43) EPS. View Entera Bio's earnings history. Who are Entera Bio's key executives? Entera Bio's management team includes the following people: Dr. Spiros Jamas Sc.D., Chief Exec. Officer (Age 61, Pay $392k)Ms. Miranda J. Toledano M.B.A., Chief Bus. Officer, CFO, Head of Corp. Strategy & Independent Director (Age 45, Pay $65.2k)Dr. Hillel Galitzer, Chief Operating Officer (Age 44, Pay $380k)Dr. Phillip Schwartz Ph.D., Exec. VP, Pres of R&D and Director (Age 60, Pay $502k)Dr. Arthur C. Santora II, M.D., Ph.D., Chief Medical Officer (Age 71) Who are some of Entera Bio's key competitors? Some companies that are related to Entera Bio include Acumen Pharmaceuticals (ABOS), ARYA Sciences Acquisition Corp IV (ARYD), INmune Bio (INMB), Fennec Pharmaceuticals (FENC), Jounce Therapeutics (JNCE), Cellectis (CLLS), Genenta Science (GNTA), Passage Bio (PASG), Poseida Therapeutics (PSTX), BioAtla (BCAB), Finch Therapeutics Group (FNCH), Big Cypress Acquisition (BCYP), Oyster Point Pharma (OYST), Armata Pharmaceuticals (ARMP) and Surrozen (SRZN). View all of ENTX's competitors. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include (CGC), Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA). When did Entera Bio IPO? (ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager. What is Entera Bio's stock symbol? Entera Bio trades on the NASDAQ under the ticker symbol "ENTX." Who are Entera Bio's major shareholders? Entera Bio's stock is owned by many different institutional and retail investors. Top institutional investors include PNC Financial Services Group Inc. (0.04%). Company insiders that own Entera Bio stock include Ramesh Ratan, Ron Mayron and Yonatan Malca. View institutional ownership trends for Entera Bio. Which institutional investors are buying Entera Bio stock? ENTX stock was bought by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc.. Company insiders that have bought Entera Bio stock in the last two years include Ramesh Ratan, Ron Mayron, and Yonatan Malca. View insider buying and selling activity for Entera Bio or or view top insider-buying stocks. How do I buy shares of Entera Bio? Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Entera Bio's stock price today? One share of ENTX stock can currently be purchased for approximately $1.62. How much money does Entera Bio make? Entera Bio (NASDAQ:ENTX) has a market capitalization of $38.39 million and generates $570 thousand in revenue each year. The company earns $-12.19 million in net income (profit) each year or ($0.16) on an earnings per share basis. How many employees does Entera Bio have? Entera Bio employs 18 workers across the globe. How can I contact Entera Bio? Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for Entera Bio is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at [email protected]. This page (NASDAQ:ENTX) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
